Olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide is filed as Thiazide Diuretic [EPC]. The sections below restate public label fields stored for this profile.
BOXED WARNING: BOXED WARNING WARNING: FETAL TOXICITY When pregnancy is detected, discontinue olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets as soon as possible. ( 5.1 , 8.1) Drugs that act directly on the renin-angiotensin system (RAS) can cause injury and death to the developing fetus. ( 5.1 , 8.1 ) WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets as soon as possible ( 5.1 ), 8.1 ). Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus ( 5.1 , 8.1 ).
Hydrochlorothiazide tablets was dizziness (1%)
Most common adverse reactions (incidence ≥2%) are dizziness, peripheral edema, headache, fatigue, nasopharyngitis, muscle spasms, nausea, upper respiratory tract infection, diarrhea, urinary tract infection, and joint swelling ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Endo at 1-800-828-9393 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Olmesartan medoxomil (7.1 ): Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia. Colesevelam hydrochloride: Consider administering olmesartan at least 4 hours before Colesevelam hydrochloride dose. Lithium: Increases in serum lithium concentrations and lithium toxicity. Amlodipine ( 7.2 ): Limit simvastatin to 20 mg daily when coadministered. Increased exposure to cyclosporin and tacrolimus Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. Cholestyramine and colestipol: Reduced absorption of thiazides. NSAIDs: Can reduce the diuretic, natriuretic, and antihypertensive effects of diuretics.
Olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide belongs to the Thiazide Diuretic [EPC] class of medications.
The FDA label lists Olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide as: Hypotension: Correct volume or salt depletion prior to administration. ( 5.2 ). Monitor renal function and potassium in susceptible patients Increased angina or myocardial infarction with calcium channel blockers may occur upon dosage initiation or increase ( 5.3 ). Observe for signs of fluid or electrolyte imbalance ( 5.6 ). Exacerbation or activation of systemic lupus erythematosus ( 5.8 ). Acute angle-closure glaucoma ( 5.9 ). Sprue-like enteropathy has been reported. Consider discontinuation of Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets in cases where no other etiology is found ( 5.10 ). Available strengths and packaging vary by manufacturer.
Yes. A generic version of Olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide is available in the U.S. Ask your pharmacist about substitution.
Our ingest of the FDA label for Olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.
The FDA Enforcement Report does not show an active/ongoing recall for Olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide in our latest ingest. Recall data can change daily — verify at FDA.gov.
The FDA label lists Bryant Ranch Prepack as a labeler/manufacturer of Olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide. Multiple firms may market generics of the same molecule.
Loading full data from Know Your Drugs Institute…